Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06527391 · ClinicalTrials.gov registry record · Phase 2
Choline and Iron Deficiency
A Phase 2 study of Anemia and Pediatric Iron Deficiency, sponsored by University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT06527391: Recruiting Phase 2 study of Anemia and Pediatric Iron Deficiency, sponsored by University of Minnesota.
NCT06527391 is a Phase 2 study of Anemia and Pediatric Iron Deficiency that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 300 participants, below the 423-participant average among 72 other Anemia trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06527391, a Phase 2 study of Anemia and Pediatric Iron Deficiency, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
BACKGROUND: Iron deficiency limits the neurodevelopmental potential of more than 200 million children each year. Iron therapy is typically started when iron deficiency anemia is first diagnosed after screening for anemia or detection of clinical symptoms of iron deficiency anemia at 12 months of age. But iron started at this time does not fully correct earlier iron-deficiency-mediated brain dysfunction, underscoring the need for low-cost, easily implementable adjunct therapies to iron to treat or prevent this dysfunction in high-risk populations. GAP Supplementation with the nutrient choline lessens damage to the hippocampus from early-life iron deficiency in pre-clinical models and improves hippocampus-mediated memory in children with Fetal Alcohol Spectrum Disorders. Choline has not been tested in children with iron deficiency anemia, despite strong pre-clinical and clinical evidence supporting a benefit to brain development. HYPOTHESIS: Infants with iron deficiency anemia who receive iron and nine months of daily choline supplements will have better scores on specific neurobehavioral tests of recognition memory than infants who receive iron and placebo. METHODS: This randomized, double-blinded, placebo-controlled clinical trial will randomize 300 6-month-old infants with iron deficiency anemia at Mulago Hospital, Kampala, Uganda, to iron plus choline or iron plus placebo to test the effect of choline on hippocampus-specific and global neurobehavioral outcomes after nine months. RESULTS: Pending IMPACT: If our hypothesis is correct, choline could be added immediately to standard-of-care treatment for iron deficiency anemia. This intervention could safely mitigate the brain dysfunction of early-life iron deficiency that is often undiagnosed until the hippocampal critical window is closing. This simple, low-cost nutrient could thus have life-long benefit for both individuals and the economic and social prosperity of entire regions.
Primary Outcome
Elicited Imitation outcomes (number of items correctly recalled and number of steps recalled in the correct order for both immediate and delayed recall) at age 15 months, i.e., after nine months of daily supplementation with choline or placebo.
Conditions Studied
Interventions
- DRUG choline bitartrate
- OTHER placebo drug
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2027-09-21 |
| Phase | Phase 2 |
What NCT06527391 shows while recruiting
NCT06527391 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 423-participant average among 72 other Anemia trials with a reported enrollment target (29% lower).
The record links to 2 conditions, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which choline bitartrate is the first listed.
NCT06527391 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06527391 about?
NCT06527391 is a clinical study titled "Choline and Iron Deficiency". BACKGROUND: Iron deficiency limits the neurodevelopmental potential of more than 200 million children each year. Iron therapy is typically started when iron deficiency anemia is first diagnosed after screening for anemia or detection of clinical symptoms of iron deficiency anemia at 12 months of ag...
What is the current status of trial NCT06527391?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2025-08-11. Estimated completion is 2027-09-21.
What conditions does trial NCT06527391 study?
This clinical trial studies the following conditions: Anemia, Pediatric Iron Deficiency.
What interventions are being tested in trial NCT06527391?
The interventions under investigation include: choline bitartrate (DRUG), placebo drug (OTHER).
Who is sponsoring clinical trial NCT06527391?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06527391 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06527391's enrollment target sits among peer trials
300 25th of 72 higher than 47 of 72 other Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
-
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI